
Klaus Weber
Related Authors
Silvia Dorado
University of Rhode Island
María Angélica Corva
Pontificia Universidad Católica Argentina
Charlene Zietsma
Pennsylvania State University
Maxim Voronov
Schulich School of Business
Devon Gidley
Queen's University Belfast
Eero Vaara
University of Oxford
Felipe Massa
University of Vermont
InterestsView All (7)
Uploads
Papers by Klaus Weber
diverse logics in their operations. The required institutional work inside organizations at that stage—institutional
intrapreneurship—involves distinctive challenges. Incumbent logics are entrenched in organizational routines, status orders,
policies, and structures that hamper change and trigger resistance. We used qualitative data from two integrative medicine (IM)
programs inside large healthcare organizations to understand how institutional intrapreneurs work to integrate the IM logic in
these highly institutionalized organizations. We found that intrapreneurs use opportunistic tactics to create and strengthen
organizational free spaces aligned with the new logic, and then leverage the capacity that is developed to extend elements of
the new logic into the broader organization. This study suggests that a better understanding of the organizational context helps
explain the fate of early-stage efforts toward institutional change
commercialization of new technologies? We suggest that the effect of movement activism
is conditioned by the internal polity and therefore varies across organizations. This
article examines how the anti-genetic movement in Germany during the 1980s affected
six domestic pharmaceutical firms’ commercialization of biotechnology. We develop a
process model of how movements penetrate the relatively closed polity of private
organizations. External contestation weakened the position of internal champions of
biotechnology, precipitated divisions among organizational elites, and undermined
collective commitment to the technology. The movement also increased perceptions of
investment uncertainty, but the consequences of this uncertainty depended on
organizational logics of decision making. As a result, investments in some firms were
tilted away from domestic biotechnology projects. The model also explains this variation
in organization-level outcomes of movement contestation.
diverse logics in their operations. The required institutional work inside organizations at that stage—institutional
intrapreneurship—involves distinctive challenges. Incumbent logics are entrenched in organizational routines, status orders,
policies, and structures that hamper change and trigger resistance. We used qualitative data from two integrative medicine (IM)
programs inside large healthcare organizations to understand how institutional intrapreneurs work to integrate the IM logic in
these highly institutionalized organizations. We found that intrapreneurs use opportunistic tactics to create and strengthen
organizational free spaces aligned with the new logic, and then leverage the capacity that is developed to extend elements of
the new logic into the broader organization. This study suggests that a better understanding of the organizational context helps
explain the fate of early-stage efforts toward institutional change
commercialization of new technologies? We suggest that the effect of movement activism
is conditioned by the internal polity and therefore varies across organizations. This
article examines how the anti-genetic movement in Germany during the 1980s affected
six domestic pharmaceutical firms’ commercialization of biotechnology. We develop a
process model of how movements penetrate the relatively closed polity of private
organizations. External contestation weakened the position of internal champions of
biotechnology, precipitated divisions among organizational elites, and undermined
collective commitment to the technology. The movement also increased perceptions of
investment uncertainty, but the consequences of this uncertainty depended on
organizational logics of decision making. As a result, investments in some firms were
tilted away from domestic biotechnology projects. The model also explains this variation
in organization-level outcomes of movement contestation.